Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: final results of the randomized, double-blind, placebo-controlled phase II MADONNA study - Mavratzas, Athanasios; Baek, Sunhwa; Schneeweiss, Andreas; Marmé, Frederik (The breast, 2019)
Gesehen am 12.08.2019